NeuroPace, Inc. (NASDAQ:NPCE) Receives $18.50 Consensus Price Target from Brokerages

NeuroPace, Inc. (NASDAQ:NPCE) has been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $18.50.

NPCE has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of NeuroPace in a report on Wednesday, November 5th. JPMorgan Chase & Co. increased their target price on shares of NeuroPace from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Wells Fargo & Company lifted their target price on shares of NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. UBS Group upped their price target on shares of NeuroPace from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroPace in a report on Monday, December 15th.

Institutional Investors Weigh In On NeuroPace

Large investors have recently made changes to their positions in the company. Tudor Investment Corp ET AL increased its holdings in NeuroPace by 29.3% in the third quarter. Tudor Investment Corp ET AL now owns 153,698 shares of the company’s stock worth $1,585,000 after buying an additional 34,807 shares during the last quarter. Armistice Capital LLC increased its stake in shares of NeuroPace by 12.6% during the 3rd quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock worth $13,382,000 after purchasing an additional 145,665 shares during the last quarter. PharVision Advisers LLC bought a new position in shares of NeuroPace during the 3rd quarter valued at $232,000. Quarry LP lifted its stake in shares of NeuroPace by 94.9% in the 3rd quarter. Quarry LP now owns 3,845 shares of the company’s stock valued at $40,000 after purchasing an additional 1,872 shares during the last quarter. Finally, Qube Research & Technologies Ltd boosted its holdings in NeuroPace by 89.8% in the third quarter. Qube Research & Technologies Ltd now owns 213,773 shares of the company’s stock worth $2,204,000 after purchasing an additional 101,136 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

NeuroPace Price Performance

NPCE opened at $16.21 on Monday. The firm has a market capitalization of $539.96 million, a P/E ratio of -21.33 and a beta of 1.85. The stock has a fifty day moving average of $13.85 and a 200-day moving average of $11.26. The company has a quick ratio of 3.94, a current ratio of 4.86 and a debt-to-equity ratio of 3.17. NeuroPace has a 12-month low of $7.56 and a 12-month high of $18.98.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.09. The firm had revenue of $27.35 million for the quarter, compared to analyst estimates of $24.64 million. NeuroPace had a negative return on equity of 136.60% and a negative net margin of 25.28%. Equities analysts forecast that NeuroPace will post -1 EPS for the current fiscal year.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.